NEW YORK, Feb. 17 (GenomeWeb News) - Chemicon International has sub-licensed an RNAi technology from Promega, the companies said today.
Under the agreement, Temecula, Calif.-based Chemicon, a research division of Serologicals, has the right to develop and sell products for DNA-directed RNA interference for life science research. Promega will also help Chemicon develop ddRNAi products for studying mammalian genes.
Madison, Wis.-based Promega holds an exclusive license for ddRNAi technology from Benitec of Queensland, Australia.